Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,523.20
(
0.83%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
105.50
(
-0.25%
)
Bitcoin
81,164.84
(
0.84%
)
News Focus
News Focus
Post# of 405212
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

CallMeCrazy

Send PM Follow Ignore
Followers 36
Posts 1471
Boards Moderated 0
Alias Born 11/12/2013

CallMeCrazy

Re: Dr Jerry post# 71929

Tuesday, 09/30/2014 9:50:59 PM

Tuesday, September 30, 2014 9:50:59 PM

Post# of 405212
Yes B is superior to both, but what I found interesting was that this study compared tedizolid aka Sivextro made by Trius Therapeutics to linezolid aka Zyvox made by Pfizer, and the study was funded by Cubist Pharmaceuticals, the maker of Cubicin aka daptomycin.

What is Cubist up to? Could this be an attempt to slow the approach of bacterial resistance to Cubicin? Hmmm.

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)70737-6/abstract

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote